Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.
While geopolitical instability in Eastern Europe would appear to make Russia a risky bet, the size of the market and incoming targets on drug production mean the likes of Abbott Laboratories are still investing. For companies unwilling or unable to strike deals like Abbott's $495 million buyout of Veropharm, a new option is tipped to emerge: CMOs.
Diversified conglomerate Danaher emphasized organic growth rather than acquisitions at a recent investor meeting. That's despite much speculation on its M&A appetite following the Medtronic announcement that it will acquire Covidien.
Abbott Laboratories has said it plans to focus its branded generics business on a select group of rapidly expanding emerging markets. It appears Russia is one of them. The Illinois-based drugmaker will shell out up to $495 million to buy the fast-growing Russian generics maker VeroPharm from local billionaire Roman Avdeev.
Multinationals may lose some of their access to Russia's vaccines market thanks to pressure from state corporation Rosteh, with 11 billion rubles ($300 million) in state contracts at stake.
Last year, multinational drugmakers had their eyes on Russian biosimilars developer Biocad. But now, it's the country's own lead pharma company that will grab the St. Petersburg-based company.
While many Big Pharma players have only recently discovered the potential of doing business in Russia, India's generic drugmaker Ranbaxy Laboratories has been there for two decades. Ranbaxy has established itself by selling the low-price copycat drugs it has made its fortunes on, but is now looking at moving up the value chain.
With a Phase III cancer immunotherapy study under way, Durham, NC-based Argos Therapeutics today put in place its fifth fundraising, banking $42.5 million from a big group of backers led by a pair of unorthodox players.
Russia's Pharmstandard is clearing the way for a proposed spinoff of its over-the-counter drugs unit--and clarifying the details for some skeptical investors.
A week after Cleveland's nascent biotech accelerator BioMotiv bumped its financial reserves to $46 million, Torrey Pines Investment has stepped in to offer a $20 million commitment and close ties to the Russian drug development industry to back a joint effort to spawn new translational drug efforts around the globe.